BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Nov 14 2025

0mins

Source: PRnewswire

Financial Update: BrainStorm Cell Therapeutics reported a net loss of approximately $2.1 million for Q3 2025, a decrease from $2.7 million in Q3 2024, with cash reserves at about $0.23 million.
NurOwn Clinical Trial Progress: The company has received FDA clearance to initiate a Phase 3b clinical trial for NurOwn, aimed at generating data to support a Biologics License Application (BLA) for ALS treatment.
Community Engagement: A Citizen Petition from the ALS community has been filed to request a renewed regulatory review of NurOwn, which BrainStorm views as a positive development reflecting interest in the therapy's potential.
Future Plans: BrainStorm plans to host a conference call in late Q4 2025 or early Q1 2026 to provide updates on the NurOwn Phase 3 program and its ongoing efforts in the ALS community.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.